Metastatic breast cancer survival according to HER2 and Topo2a gene status

Disease Markers

Volumn 26, Issue 4, 2009, Pages 171-180

  Todorović Raković, Nataša ^a   Neskovic Konstantinovic Z ^a   Nikolic Vukosavljevic D ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

CISH; HER2; Metastatic breast cancer; Topo2a

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHROMOGENIC IN SITU HYBRIDIZATION; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR GENE;

EID: 70349090509     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/808947     Document Type: Article

References (26)

1. P. Kauranemi, M. Barlund, O. Monni and A. Kallionemi, New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays, Cancer Research 61 (2001), 8235-8240.
2. T.A. Jarvinen, M. Tanner, M. Barlund, A. Borg and J. Isola, Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer, Genes Chromosomes Cancer 26 (1999), 142-150.
3. T.A. Jarvinen, M. Tanner, V. Rancancen et al., Amplification and deletion of topoisomerase2a gene are common in ErbB2 amplified breast cancer and alter sensitivuty to doxorubicin, American Journal of Pathology 156 (2000), 839-847.
4. V. Durbecq, C. Desmed, M. Paesmans, F. Cardoso, A. Di Leo, M. Mano et al., Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer, Int J Oncol 5 (2004), 1473-1479.
5. J.C. Wang, DNA topoisomerases, Annu Rev Biochem 65 (1996), 635-692.
6. A. Di leo and J. Isola, Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clinical Breast Cancer 4 (2003), 179-186.
7. P. Fritz, C.M. Carbera, J. Dippon, A. Gerteis, W.E. Simon Waultzky et al., C-erbB2 and topoisomerase2a protein ex-pressio independently predict poor survival in primary human breast cancer: a retrospective study, Breast Cancer Reserach 7 (2005), R374-R384.
8. C. Bernard-Marty, F. Cardoso and M. Piccart, Facts and controversies in systemic treatment of breast cancer, The Oncolo-giest 9 (2004), 617-632. (Pubitemid 39546403)
9. A. Vincent-Salomon, M. Jouve, P. Genin, P. Freneaux, B. Sigal-Zafrany, M. Caly et al., HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process, Cancer 94 (2002), 2169-2173.
10. D.J. Slamon, G.M. Clark, G.C. Chamness, A. Ulrich and W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2 oncogene, Science 235 (1987), 177-181.
11. T.A. Jarvinen, J. Kononen, M. Pelto-Huikko and J. Isola, Expression of topoisomerase 2alpha is associated with rapid cell proliferation, aneuploidy and c-erbB2 expression in breast cancer, Am J Pathol 148 (1996), 2073-2082.
12. L. Depowski, S.L. Rosenthal, T.M. Brien, S. Stylis, R.L. Johnson and J.S. Ross, Topoisomerase 2 alpha expression in breast cancer: correaltion with clinical variables, Mod Pathol 13 (2000), 542-547.
13. H. Turley, M. Comley, S. Houlbrook, N. Nozaki, A. Kikuchi, I.D. Hickson et al., The distribution and expression of the two isofdorms of DNA topoisomerase II in normal and neoplastic human tissues, British Journal of Cancer 75 (1997), 1340-1346.
14. M. Collozza, A. Sidoni, A.M. Mosconi, A. Cavaliere, G. Bisagni, S. Gori et al., HER2 overexpression as pre-dictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epiru-bicin in patients with stage I/II breast cancer: long-term results, Clin Breast Cancer 6 (2005), 253-259.
15. J.J. Champoux, DNA topoisomerases: Structures, function and mechanism, Annu Rev Biochem 70 (2001), 369-413.
16. F. Cardoso, V. Durbecq, D. Larsimont, M. Paesmans, J.Y. Leroy, G. Rouas et al., Correlation between complete response to anthracycline-based chemotherapy and topoisomearse 2al-pha gene amplification and protein overexpression in locally advanced/metastatic breast cancer, International Journal of Oncology 24 (2004), 201-209.
17. M. Marti-Richard, M. Munoz, J. Albanell, L. Colomo, M. Beller, M.J. Rey et al., Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy, Oncology 66 (2004), 388-394.
18. L.N. Harris, L. Yang, V. Liotcheva, S. Pauli, J.D. Iglehart, O.M. Colvin et al., Induction of Topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy, Clinical Cancer Research 7 (2002), 1497-1504.
19. F. Manna Edel, L.C. Teixeira and M. Alvarenga, Association between immunohistochemical expression of topoisomerase IIalpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer, Tumori 92 (2006), 222-229.
20. S. Paik. J. Bryant, E. Tan-Chiu, G. Yothers, C. Park, D.L. Wickerham et al., HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15, Journal of National Cancer Institute 92 (2000), 1991-1998.
21. D.W. Miles, W.H. Harris, C.E. Gillett et al., Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophos-phamide/methotrexate/fluorouracil, Interantional Journal of Cancer 84 (1999), 354-359.
22. S. Menard, P. Valagussa, S. Pilatti, L. Gianni, E. Biganzoli, P. Borachi et al., Response to cyclophosphamide, mehotrexate and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables, Journal of Clinical Oncology 19 (2001), 329-335.
23. B.A. Gusterson, R.D. Gelber, A. Goldhirsch et al., Prognostic importance of c-erb B2 expression in breast cancer, Journal of Clinical Oncology 10 (1992), 1049-1056.
24. J.G.M. Klijn, E.M.J.J. Bern and J.A. Fockens, Prognostic fac-trors and response to therapy in breast cancer, Cancer Surv 18 (1993), 165-198.
25. P. Rudolph, H. Olsson, G. Bonatz et al., Correlation between p53, c-erbB2 and topoisomerase 2alpha expression:DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas, Prognostic implications, J Pathol 187 (1999), 207-217.
26. M.S. Orr, P.M. O Connor and K.W. Kohn, Effects of c-erbB2 overexpression on the drug sensitivities of nornmal human mammary epithelial cells, J Natl Cancer Inst 92 (2000), 987-994.